Who
Chris Storgard
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Design Therapeutics; Chief Medical Officer, Fate Therapeutics.
In numbers
- Trades disclosed
- 8
- Buys
- 1
- Sells
- 0
- Bought
- $100K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 May 2016
- Last trade
- 2 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 5 Jan 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 1 May 2025filed 23 May 2025 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 16 Jan 2018filed 17 Jan 2018 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,000 | filing |
| 4 Jan 2017filed 6 Jan 2017 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 | filing |
| 23 Nov 2016filed 28 Nov 2016 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K37,593 at $2.66 | filing |
| 16 May 2016filed 18 May 2016 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —9,090 at $0.00 | filing |
| 16 May 2016filed 18 May 2016 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 | filing |
News
Analyzing Fate Therapeutics (NASDAQ:FATE) & Applied Therapeutics (NASDAQ:APLT)FATE · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Chris Storgard; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.